Vivo Bio Tech Profile
Key Indicators
- Authorised Capital ₹ 20.00 Cr
- Paid Up Capital ₹ 14.90 Cr
- Company Age 37 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 174.91 Cr
- Satisfied Charges ₹ 65.17 Cr
- Revenue Growth -0.71%
- Profit Growth -61.24%
- Ebitda -10.46%
- Net Worth 10.82%
- Total Assets 55.61%
About Vivo Bio Tech
Vivo Bio Tech Limited (VBTL) is a leading Public Limited Indian Non-Government Company incorporated in India on 12 February 1987 and has a history of 37 years and 11 months. Its registered office is in Hyderabad, Telangana, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 511509.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 20.00 Cr and a paid-up capital of Rs 14.90 Cr.
The company currently has active open charges totaling ₹174.91 Cr. The company has closed loans amounting to ₹65.17 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Vivo Bio Tech Limited India are Vaishnavi Ayinampudi as COMPANY SECRETARY and Sri Kompella as Cfo. Kalyan Mangipudi, Sankaranarayanan Alangudi, Sri Kompella, and Three other members serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
L65993TG1987PLC007163
-
Company No.
007163
-
Stock Symbol
BSE : 511509
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
12 Feb 1987
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Listed
-
ROC Code
Roc Hyderabad
Industry
What products or services does Vivo Bio Tech Limited offer?
Vivo Bio Tech Limited offers a wide range of products and services, including Medical Surgery & Treatment Centres, Medical Treatment Services.
Who are the key members and board of directors at Vivo Bio Tech?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vaishnavi Ayinampudi | Company Secretary | 29-Jan-2024 | Current |
| Sri Kompella | CFO | 06-Jan-2022 | Current |
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shivanand Karopadi
|
Director | 01-Apr-2021 | Current |
|
Sankaranarayanan Alangudi
|
Whole-Time Director | 27-May-2016 | Current |
|
Kalyan Mangipudi
|
Whole-Time Director | 26-Nov-2009 | Current |
|
Sri Kompella
|
Whole-Time Director | 03-Nov-2021 | Current |
|
Shyam Tipparaju
|
Director | 31-Aug-2023 | Current |
|
Kunda Kalpana
|
Director | 30-Jun-2020 | Current |
Financial Performance of Vivo Bio Tech.
Vivo Bio Tech Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 0.71% decrease. The company also saw a substantial fall in profitability, with a 61.24% decrease in profit. The company's net worth Soared by an impressive increase of 10.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vivo Bio Tech?
In 2023, Vivo Bio Tech had a promoter holding of 42.08% and a public holding of 57.91%. The company had 4 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Virinchi LimitedSri Kompella, Shyam Tipparaju and 1 more are mutual person
-
Virinchi Infra And Realty Private Limited
Sri Kompella is a mutual person
-
Virinchi Learning Private Limited
Sri Kompella is a mutual person
-
Virinchi Combinatorics And Systems Biology Private Limited
Sri Kompella is a mutual person
-
Virinchi Health Care Private LimitedSri Kompella and Shyam Tipparaju are mutual person
-
Asclepius Consulting & Technologies Private LimitedShyam Tipparaju is a mutual person
Charges (Loans)
₹174.91 Cr
₹65.17 Cr
Charges Breakdown by Lending Institutions
- Canara Bank : 130.44 Cr
- Others : 33.27 Cr
- Department Of Biotechnology : 5.70 Cr
- The South Indian Bank Limited : 4.80 Cr
- Canara Bank Ltd : 0.59 Cr
- Others : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Oct 2023 | Others | ₹18.00 Cr | Open |
| 17 Oct 2023 | Others | ₹3.94 Cr | Open |
| 17 Oct 2023 | Others | ₹3.00 Cr | Open |
| 18 Aug 2023 | The South Indian Bank Limited | ₹2.65 Cr | Open |
| 05 Dec 2022 | Canara Bank | ₹2.09 M | Open |
How Many Employees Work at Vivo Bio Tech?
Vivo Bio Tech has a workforce of 5 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vivo Bio Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vivo Bio Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
